Is low-dose naltrexone (LDN) effective for chronic pain?

Low-Dose Naltrexone for Chronic Pain

Low-dose naltrexone (LDN) shows promise as a second-line treatment option for specific chronic neuropathic pain conditions, particularly fibromyalgia, but should not be used as a first-line agent for general chronic pain management.

Evidence-Based Positioning

The 2017 Ophthalmology guideline positions LDN as an off-label treatment for chronic neuropathic pain conditions including fibromyalgia, complex regional pain syndrome, low-back pain, and painful diabetic neuropathy 1. The mechanism involves antagonism of toll-like receptor 4, reducing pro-inflammatory cytokines and modulating microglial activity—distinct from traditional opioid antagonism 1.

However, the FDA-approved indications for naltrexone are limited to alcohol use disorder and opioid use disorder at standard doses (50 mg daily) 2. Low-dose use (1.5-4.5 mg) for pain remains entirely off-label.

Clinical Evidence by Pain Type

Neuropathic Pain (Including Fibromyalgia)

• Fibromyalgia: An RCT of 31 patients demonstrated that LDN 4.5 mg significantly decreased pain and improved life satisfaction compared to placebo 1
• A 2025 meta-analysis found LDN superior to placebo specifically in fibromyalgia [d = -0.34, P = 0.0186] but showed no significant difference for chronic pain overall 3
• The 2018 Annual Review of Medicine notes that pregabalin, duloxetine, and milnacipran have the strongest evidence for fibromyalgia, with FDA approval 4

Musculoskeletal Pain

• A 2023 RCT in osteoarthritis and inflammatory arthritis found no difference between LDN and placebo for pain interference (P = 0.90) or pain severity 5
• The 2017 HIV/IDSA guideline recommends acetaminophen and NSAIDs as first-line for musculoskeletal pain (strong recommendation, high evidence) 6

General Chronic Pain

• A 2024 systematic review of 7 RCTs (406 patients) concluded that LDN is not effective in managing chronic pain across diverse conditions 7
• A 2025 Veterans Affairs study showed only a -0.83 average change in pain scores, described as "small decrease" 8

Treatment Algorithm

First-Line Agents (Use These First):

• Neuropathic pain: TCAs (nortriptyline 10-100 mg at bedtime), SNRIs (duloxetine), or gabapentinoids 1, 4, 9
• Musculoskeletal pain: Acetaminophen or NSAIDs 6
• Fibromyalgia: Pregabalin, duloxetine, or milnacipran 4

Second-Line Consideration for LDN:

• Patient has failed first-line neuropathic pain medications
• Diagnosis of fibromyalgia with inadequate response to FDA-approved agents
• Patient cannot tolerate standard medications due to side effects
• Dosing: Start 1.5 mg at bedtime, increase by 1.5 mg every 2 weeks to maximum 4.5 mg 1

Do NOT use LDN for:

• First-line treatment of any chronic pain condition
• Nociceptive pain (osteoarthritis, mechanical low back pain) 5
• When patient is currently taking opioids (requires 7-10 day opioid-free interval minimum) 2

Critical Caveats

Opioid Interaction Risk: The FDA label explicitly warns that patients must be opioid-free for 7-10 days before starting naltrexone to avoid precipitated withdrawal 2. Patients transitioning from buprenorphine or methadone may experience severe withdrawal for up to 2 weeks 2.

Common Side Effects: Headache, tachycardia, vivid dreams, drowsiness, dizziness, and nausea occur in approximately 32% of patients 1, 8. These are generally mild but can affect adherence.

Dosing Variability: Recent evidence suggests the effective dose is highly idiosyncratic, ranging from 0.1-4.5 mg daily 10. This supports gradual titration rather than fixed dosing, though this adds complexity to management.

Evidence Quality: Most LDN studies have small sample sizes, short follow-up periods (typically <3 months), and inconsistent methodologies 7, 8. The 2025 meta-analysis rated the certainty of evidence as low 3.

Practical Implementation

When prescribing LDN after first-line failures:

1. Confirm patient is completely opioid-free (including tramadol) for minimum 7-10 days
2. Start 1.5 mg at bedtime
3. Increase by 1.5 mg every 2 weeks based on response
4. Maximum dose 4.5 mg at bedtime
5. Reassess at 8-12 weeks; discontinue if no meaningful benefit
6. Monitor for vivid dreams (most common complaint) and adjust timing if needed

The evidence does not support LDN as superior to established first-line treatments, and it should be reserved for patients who have documented inadequate response to guideline-recommended therapies, particularly in fibromyalgia where some positive signal exists 1, 3.